low-dose radiotherapy + serplulimab + bevacizumab + irinotecan + albumin-bound paclitaxel

This is an investigational multi-agent combination regimen being evaluated in a Phase II clinical trial (NCT06165458) sponsored by Zhejiang Cancer Hospital. The regimen consists of low-dose radiotherapy (LDR) sequentially combined with the anti-PD-1 monoclonal antibody serplulimab, a bevacizumab analog (anti-VEGF), and systemic chemotherapy (either irinotecan or albumin-bound paclitaxel). It is specifically designed for patients with gastric cancer and peritoneal metastases (peritoneal carcinomatosis). The rationale for this combination is to leverage LDR as an immunomodulatory sensitizer to enhance the efficacy of PD-1 blockade and anti-angiogenic therapy, while cytotoxic chemotherapy provides direct anti-tumor activity. In the clinical trial setting, the bevacizumab analog is administered via local intraperitoneal infusion to target peritoneal disease directly.

Other names

LDR + serplulimab + bevacizumab analog + irinotecan/nab-paclitaxelLDR + Immunochemotherapy in Gastric Cancer With Peritoneal Carcinomatosis